Tempus AI Sets Clinical Availability for Whole-Genome Sequencing Test Amid Investor Skepticism

Tempus AI Inc. (NASDAQ:TEM) has announced that its first whole‑genome sequencing assay, xH, will be clinically availab...

Read story →